Skip to content

Harmony Biosciences

US · HRMY #2681 by market cap Listed 2020
32.59 -0.39 -1.18%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

About Harmony Biosciences

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Founded
2017
CEO
Dr. Jeffrey M. Dayno, M.D.
Employees
293
Headquarters
Plymouth Meeting, Pennsylvania, United States of America
Fiscal year end
12-31
Website
harmonybiosciences.com

Company profile

Exchange
US
Symbol
HRMY
Market-cap rank
#2681
Listing date
2020-08-19
Market cap
1.91B
Float cap
1.71B
Shares out
58.72M
Float shares
52.58M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 20:02:36 · For reference only, not investment advice and not tailored to your situation.

Harmony Biosciences discussion 0 comments

Add a comment